JO2932B1 - Pegylated insulin lispro compounds - Google Patents

Pegylated insulin lispro compounds

Info

Publication number
JO2932B1
JO2932B1 JO2009195A JOP20090195A JO2932B1 JO 2932 B1 JO2932 B1 JO 2932B1 JO 2009195 A JO2009195 A JO 2009195A JO P20090195 A JOP20090195 A JO P20090195A JO 2932 B1 JO2932 B1 JO 2932B1
Authority
JO
Jordan
Prior art keywords
insulin lispro
relates
pegylated insulin
lispro compounds
pegylated
Prior art date
Application number
JO2009195A
Other languages
Arabic (ar)
Inventor
لي شان
زهانج ليانشان
دويل براندون
شيراني شهرير
مايكل بيلز جون
باتلير كاتلير، جيه ار جوردون
جون هانسين ريان
Original Assignee
ايلي ليلي اند كومباني
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41110836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO2932(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ايلي ليلي اند كومباني filed Critical ايلي ليلي اند كومباني
Application granted granted Critical
Publication of JO2932B1 publication Critical patent/JO2932B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
JO2009195A 2008-06-13 2009-05-31 Pegylated insulin lispro compounds JO2932B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6128108P 2008-06-13 2008-06-13
US12139408P 2008-12-10 2008-12-10

Publications (1)

Publication Number Publication Date
JO2932B1 true JO2932B1 (en) 2015-09-15

Family

ID=41110836

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2009195A JO2932B1 (en) 2008-06-13 2009-05-31 Pegylated insulin lispro compounds

Country Status (34)

Country Link
US (3) US20110105392A1 (en)
EP (2) EP2476430B1 (en)
JP (2) JP4890662B2 (en)
KR (1) KR101238979B1 (en)
CN (1) CN102065884B (en)
AR (1) AR071990A1 (en)
AT (1) ATE554786T1 (en)
AU (1) AU2009257597B2 (en)
BR (1) BRPI0915838A2 (en)
CA (1) CA2727825C (en)
CL (1) CL2009001340A1 (en)
CO (1) CO6331292A2 (en)
CY (2) CY1112977T1 (en)
DK (2) DK2288375T3 (en)
DO (1) DOP2010000379A (en)
EA (1) EA028657B1 (en)
EC (1) ECSP10010677A (en)
ES (2) ES2383496T3 (en)
HK (2) HK1149713A1 (en)
HR (2) HRP20120397T1 (en)
IL (1) IL209265A (en)
JO (1) JO2932B1 (en)
MA (1) MA32394B1 (en)
MX (1) MX2010013837A (en)
MY (1) MY158890A (en)
NZ (1) NZ588997A (en)
PE (2) PE20091960A1 (en)
PL (2) PL2476430T3 (en)
PT (2) PT2288375E (en)
RS (1) RS52361B (en)
SI (2) SI2476430T1 (en)
TW (1) TWI451876B (en)
WO (1) WO2009152128A1 (en)
ZA (1) ZA201008174B (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2264065B1 (en) * 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
CN101389650B (en) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 Compositions comprising an acylated insulin and zinc and method of making the said compositions
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
JP5749155B2 (en) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス Protease stabilized acylated insulin analogue
EP3228320B1 (en) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Combination of an insulin and a glp-1 agonist
ES2607003T3 (en) * 2008-10-30 2017-03-28 Novo Nordisk A/S Treatment of diabetes mellitus using insulin injections with an injection frequency less than daily
KR20110126591A (en) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 Glucagon analogues
CA2747112A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
KR101593406B1 (en) 2008-12-15 2016-02-12 질랜드 파마 에이/에스 Glucagon analogues
JP5635529B2 (en) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ Glucagon analog
ES2537287T3 (en) 2009-07-13 2015-06-05 Zealand Pharma A/S Acylated glucagon analogs
US8454956B2 (en) * 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
AR080669A1 (en) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION INCLUDING A GLP-1 AGONIST, AN INSULIN AND METIONIN
UY33025A (en) 2009-11-13 2011-06-30 Sanofi Aventis Deustschland Gmbh PHARMACEUTICAL COMPOSITION INCLUDING A GLP-1 METIONINE AGONIST
CN107693791B (en) 2010-02-26 2022-06-07 诺沃—诺迪斯克有限公司 Compositions comprising stable antibodies
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (en) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
WO2011141407A1 (en) * 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
US8637458B2 (en) * 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
US9878012B2 (en) * 2010-05-18 2018-01-30 Neumedicines, Inc. IL-12 formulations for enhancing hematopoiesis
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
AU2011257219B2 (en) * 2010-05-28 2014-12-04 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
AR081975A1 (en) 2010-06-23 2012-10-31 Zealand Pharma As GLUCAGON ANALOGS
KR20190050871A (en) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 Diabetes therapy
MX2012014961A (en) 2010-06-24 2013-02-26 Zealand Pharma As Glucagon analogues.
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX339614B (en) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2.
HRP20220796T1 (en) 2010-10-01 2022-10-14 ModernaTX, Inc. Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
BR112013010345A2 (en) 2010-10-27 2017-07-25 Novo Nordisk As diabetes mellitus treatment using insulin injections administered at varying injection intervals
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA3140885A1 (en) 2010-12-13 2012-06-21 Quiapeg Pharmaceuticals Ab Functionalized polymers
US20140011733A1 (en) 2011-01-20 2014-01-09 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
CN102675452B (en) * 2011-03-17 2015-09-16 重庆富进生物医药有限公司 Tool continues the conjugate of insulin human that is hypoglycemic and that combined by height and analogue
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI565714B (en) * 2011-06-02 2017-01-11 韓美科學股份有限公司 Non-peptidyl polymer-insulin multimer and method for producing the same
KR101874401B1 (en) * 2011-06-17 2018-07-04 할로자임, 아이엔씨 Stable formulations of a hyaluronan-degrading enzyme
EP2741765B9 (en) * 2011-08-10 2016-09-28 Adocia Injectable solution of at least one type of basal insulin
RU2650616C2 (en) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Pharmaceutical combination for use in glycemic control in patients with type 2 diabetes mellitus
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RS63244B1 (en) 2011-12-16 2022-06-30 Modernatx Inc Modified mrna compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
AR090843A1 (en) * 2012-05-09 2014-12-10 Lilly Co Eli TREATMENT FOR DIABETES COMORBID WITH CHRONIC RENAL DISEASE
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
EP2858678B1 (en) 2012-06-12 2019-08-07 QuiaPEG Pharmaceuticals AB Conjugates of biologically active molecules to functionalized polymers
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
CA2878991C (en) 2012-07-23 2021-12-07 Zealand Pharma A/S Glucagon analogues
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
AU2013346624B2 (en) * 2012-11-13 2018-08-09 Adocia Quick-acting insulin formulation including a substituted anionic compound
PL2922554T3 (en) 2012-11-26 2022-06-20 Modernatx, Inc. Terminally modified rna
EP2931301B2 (en) 2012-12-17 2021-09-15 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN110354255B (en) 2013-04-03 2024-05-14 赛诺菲 Treatment of diabetes by long acting insulin formulations
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US9896495B2 (en) 2013-10-17 2018-02-20 Zealand Pharma A/S Acylated glucagon analogues
KR102310392B1 (en) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 Glucagon-glp-1-gip triple agonist compounds
JP6682432B2 (en) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ GIP-GLP-1 dual agonist compounds and methods
CN105092490B (en) * 2014-05-04 2019-08-09 重庆派金生物科技有限公司 Actrapid monotard and the like or conjugate Bioactivity measuring method
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
WO2016066744A2 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
CN107206058A (en) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 Insulin glargine/lixisenatide fixed ratio preparaton
US9808011B2 (en) 2014-12-15 2017-11-07 Biovectra Inc. Pentacyclic triterpene compounds and uses thereof
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
KR20170137198A (en) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 Acylated glucagon analogs
JO3749B1 (en) * 2015-08-27 2021-01-31 Lilly Co Eli Rapid-acting insulin compositions
AR107560A1 (en) 2016-02-24 2018-05-09 Lilly Co Eli COMPOUND THAT DECREASES GLUCOSE IN BLOOD
ES2886837T3 (en) 2016-12-16 2021-12-21 Novo Nordisk As Pharmaceutical compositions containing insulin
WO2018153506A1 (en) * 2017-02-22 2018-08-30 Adocia Fast-acting insulin composition comprising a citric acid salt
EP4011396A1 (en) 2017-03-10 2022-06-15 QuiaPEG Pharmaceuticals AB Releasable conjugates
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. Rna formulations
AU2018326799A1 (en) 2017-08-31 2020-02-27 Modernatx, Inc. Methods of making lipid nanoparticles
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
FR3083700B1 (en) * 2018-07-13 2021-03-12 Adocia THERMOSTABLE FORMULATION OF HUMAN INSULIN A21G
FR3084585B1 (en) * 2018-08-03 2020-11-06 Adocia SOLUTION FOR INJECTION AT PH 7 INCLUDING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS
BR112021004689A2 (en) 2018-09-12 2021-06-08 Quiapeg Pharmaceuticals Ab releasable glp-1 conjugates
CN113271926A (en) 2018-09-20 2021-08-17 摩登纳特斯有限公司 Preparation of lipid nanoparticles and methods of administration thereof
CN113801236A (en) * 2020-06-11 2021-12-17 宁波鲲鹏生物科技有限公司 Preparation method of insulin lispro
TW202409070A (en) 2022-05-18 2024-03-01 美商普羅托莫科技公司 Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DK347086D0 (en) 1986-07-21 1986-07-21 Novo Industri As NOVEL PEPTIDES
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE10075034I1 (en) 1987-02-25 2001-05-23 Novo Nordisk As Insulin derivatives
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
PL178466B1 (en) 1993-09-17 2000-05-31 Novo Nordisk As Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
PE79099A1 (en) * 1997-06-13 1999-08-24 Lilly Co Eli STABLE INSULIN FORMULATIONS
AU1870099A (en) * 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
ES2228728T3 (en) * 1998-10-16 2005-04-16 Novo Nordisk A/S STABLE CONCENTRATED INSULIN PREPARATIONS FOR PULMONARY ADMINISTRATION.
AU2001220765A1 (en) * 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
AU2001238595A1 (en) 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
CN101045166A (en) * 2001-05-21 2007-10-03 耐科塔医药公司 Pulmonary administration of chemically modified insulin
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
SK2432004A3 (en) * 2001-12-20 2005-04-01 Eli Lilly And Company Insulin compound having protracted activity
CA2521784C (en) * 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
CN1777440A (en) * 2003-04-11 2006-05-24 Pr药品有限公司 Method for preparation of site-specific protein conjugates
US8710181B2 (en) * 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
US20060045866A1 (en) 2004-09-01 2006-03-02 Chris Chappelow Novel high purity and high molecular weight mPEG alcohol compositions
US7199193B2 (en) 2004-09-28 2007-04-03 Dow Global Technologies, Inc. Polyethylene glycol compounds and process of making
EP2505207B1 (en) * 2005-01-14 2015-04-22 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
EP1843790A2 (en) * 2005-01-27 2007-10-17 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
US7824919B2 (en) 2005-03-04 2010-11-02 Dr. Reddy's Laboratories Limited Method for analyzing activated polyethylene glycol compounds
EP1863840A1 (en) * 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
EP1881850B1 (en) * 2005-05-13 2010-09-29 Eli Lilly And Company Glp-1 pegylated compounds
WO2007075534A2 (en) * 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
ES2542146T3 (en) * 2006-07-31 2015-07-31 Novo Nordisk A/S PEGylated extended insulin.
WO2008084051A1 (en) 2007-01-12 2008-07-17 Novo Nordisk A/S Mixtures of pegylated insulin and fast acting insulin for pulmonary administration
TWI394580B (en) * 2008-04-28 2013-05-01 Halozyme Inc Super fast-acting insulin compositions

Also Published As

Publication number Publication date
EP2288375A1 (en) 2011-03-02
NZ588997A (en) 2012-03-30
SI2476430T1 (en) 2014-07-31
PL2288375T3 (en) 2012-09-28
CL2009001340A1 (en) 2010-06-04
DOP2010000379A (en) 2011-03-31
EA028657B1 (en) 2017-12-29
ECSP10010677A (en) 2011-01-31
US9050371B2 (en) 2015-06-09
TW201010728A (en) 2010-03-16
MY158890A (en) 2016-11-30
ZA201008174B (en) 2012-04-25
US20110105392A1 (en) 2011-05-05
TWI451876B (en) 2014-09-11
IL209265A0 (en) 2011-01-31
PT2288375E (en) 2012-05-17
PL2476430T3 (en) 2014-09-30
CA2727825A1 (en) 2009-12-17
ES2383496T3 (en) 2012-06-21
HRP20120397T1 (en) 2012-06-30
HK1170659A1 (en) 2013-03-08
EP2476430A1 (en) 2012-07-18
JP2012092124A (en) 2012-05-17
PE20140974A1 (en) 2014-08-25
KR20110017879A (en) 2011-02-22
CY1112977T1 (en) 2016-04-13
PE20091960A1 (en) 2010-01-15
AR071990A1 (en) 2010-07-28
BRPI0915838A2 (en) 2015-11-03
DK2288375T3 (en) 2012-05-21
CO6331292A2 (en) 2011-10-20
CN102065884B (en) 2014-11-05
CY1115354T1 (en) 2017-01-04
EA201170020A1 (en) 2011-10-31
AU2009257597B2 (en) 2011-10-06
AU2009257597A8 (en) 2011-01-06
CN102065884A (en) 2011-05-18
PT2476430E (en) 2014-07-25
JP4890662B2 (en) 2012-03-07
IL209265A (en) 2014-08-31
HRP20140480T1 (en) 2014-07-04
WO2009152128A1 (en) 2009-12-17
ES2473580T3 (en) 2014-07-07
HK1149713A1 (en) 2011-10-14
KR101238979B1 (en) 2013-03-05
ATE554786T1 (en) 2012-05-15
US20150297681A1 (en) 2015-10-22
MA32394B1 (en) 2011-06-01
RS52361B (en) 2012-12-31
CA2727825C (en) 2014-10-21
MX2010013837A (en) 2011-05-03
US20090312236A1 (en) 2009-12-17
DK2476430T3 (en) 2014-06-02
JP5336572B2 (en) 2013-11-06
JP2011524357A (en) 2011-09-01
AU2009257597A1 (en) 2009-12-17
EP2288375B1 (en) 2012-04-25
EP2476430B1 (en) 2014-05-14
SI2288375T1 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
JO2932B1 (en) Pegylated insulin lispro compounds
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
EP1988910A4 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
UA101497C2 (en) Conjugates of factor ix with increased half-life
WO2009135190A3 (en) Therapeutic calcium phosphate particles and methods of making and using same
MX342423B (en) 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients.
MY162146A (en) Pharmaceutical composition
EA201170040A1 (en) THERAPEUTIC POLYMER NANOPARTICLES CONTAINING VINCA ALKALOIDS, AND METHODS FOR THEIR RECEIVING AND APPLICATION
EA200870219A1 (en) STABILIZED WITH VITAMIN E SUCCINAT PHARMACEUTICAL COMPOSITIONS, METHODS FOR THEIR PRODUCTION AND USE
MX2008001706A (en) Conjugates of a g-csf moiety and a polymer.
WO2008094834A3 (en) Multi-functional drug carriers
WO2008106129A3 (en) Polymeric micelles for combination drug delivery
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
MY155695A (en) Quinoxalinedione derivatives
MX2013012934A (en) Polymeric nanoparticles for drug delivery.
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
PH12018500449A1 (en) Polymeric bile acid nanocompositions targeting the pancreas and colon
WO2014006502A8 (en) Protozoan variant-specific surface proteins (vsp) as carriers for oral drug delivery
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2012092305A3 (en) Nanonized iron compositions and methods of use thereof
MX337358B (en) Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof.
WO2008052046A3 (en) Compositions for coating cell membranes and methods of use thereof
HK1123986A1 (en) Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid
WO2012165916A3 (en) Non-peptidyl polymer-insulin multimer and method for producing the same
TN2010000568A1 (en) Pegylated insulin lispro compounds